

Help ease the pain of vaccinations with emla®

Whether you're going for a vaccine*, getting a blood test, need an I.V. at the hospital, or are undergoing a minor dermatological procedure, emla® is there to help ease the pain and stress.

Product Information

Unique Product Code



emla® cream

30 g tube

678045000394



emla® cream

5 g tube
with 2 Tegaderm™
dressings

678045000387



emla® cream

5 x 5 g tube
with 10 Tegaderm™
dressings

678045000370



emla® patch

2 x 1 g patches

678045000363



emla® patch

20 x 1 g patches

678045000547

* emla® is approved for use with the following vaccines: MMR (Measles-Mumps-Rubella), DPTP (Diphtheria-Pertussis-Tetanus-Poliovirus), Haemophilus influenzae b, and Hepatitis B.

EMLA[®] should only be used for the approved indications because maximum safe doses for other uses are not known. Serious and life-threatening adverse events have occurred when EMLA[®] cream was applied to large areas of skin for topical analgesia during cosmetic procedures (e.g., laser depilation)

EMLA[®] Cream (lidocaine 2.5% and prilocaine 2.5%) is indicated for use in:

Topical analgesia of intact skin in connection with

- needle insertion, e.g., i.v. catheters or prior to blood sampling;
- vaccination with only the following vaccines that have been shown not to interact with EMLA[®] in clinical trials (see Part II: CLINICAL TRIALS; Topical Analgesia in Pediatrics; Vaccination): MMR, DTP; Haemophilus influenzae b and Hepatitis B. Since the effect of EMLA[®] on the immune response to any other vaccine is unknown, it cannot be recommended for use with other vaccines;
- superficial surgical procedures, e.g., removal of molluscum contagiosum, split skin grafting, electrolysis;
- laser treatment for superficial skin surgeries, such as treatment of telangiectasia, port wine stains, warts, moles, skin nodules, and scar tissue.

Topical analgesia of genital mucosa in connection with

- local infiltration anesthesia;
- surgical procedures lasting not longer than 10 minutes on small superficial localized lesions, e.g., removal of condylomata by laser or cauterly, and biopsies.

Topical analgesia of leg ulcers in connection with

- mechanical/sharp cleansing/debridement, e.g., the removal of necrotic tissue and debris by curettes, scissors, tweezers, etc.

EMLA[®] Patch (lidocaine 2.5% and prilocaine 2.5%) is indicated for use in:

Topical analgesia of intact skin in connection with

- needle insertion, e.g., i.v. catheters or prior to blood sampling;
- vaccination with only the following vaccines that have been shown not to interact with EMLA[®] in clinical trials (see Part II: CLINICAL TRIALS; Topical Analgesia in Pediatrics; Vaccination): MMR, DTP; Haemophilus influenzae b and Hepatitis B. Since the effect of EMLA[®] on the immune response to any other vaccine is unknown, it cannot be recommended for use with other vaccines.

Consult the Product Monograph at <http://aspenpharma.ca/download/1505/> for important information about contraindications, the most serious warnings and precautions, relevant warnings and precautions, conditions of clinical use, adverse reactions, drug interactions, and dosing instructions.

The Product Monograph is also available by calling Aspen Medical Information at: 1 (844) 330-1213.

References:

1. Product Monograph, EMLA[®] Cream and EMLA[®] Patch. Date of revision: August 9, 2019.

Trademarks are owned by or licensed to the Aspen Group of companies.

© 2020 Aspen Group of companies or its licensor. All rights reserved.

Aspen Pharmacare Canada Inc.
8 – 1155 North Service Road West, Oakville, ON, L6M 3E3
www.aspenpharma.ca

CA-LIDP-01-21-#####